Overview

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women

Status:
Completed

Trial end date:
2004-12-24

Target enrollment:

Participant gender:

Summary

The primary objective was to evaluate the safety and tolerability of denosumab (AMG 162) after a single subcutaneous administration in Japanese postmenopausal women.

Phase:

Phase 1

Details

Lead Sponsor:

Amgen

Treatments:

Denosumab